However, many studies have found that CDKN2A is related to poor prognosis in bladder cancer, pancreatic adenocarcinoma, hepatocellular carcinoma (HCC), and so on [47–49]. This evidence concerns the gene CDKN2A and urinary bladder carcinoma.